WASHINGTON - The Obama administration on Wednesday said that 7.3 million people have selected 2015 healthcare plans as of Jan. 23, through the federal insurance marketplace set up under the law known as Obamacare.
NEW YORK - Some insurers selling policies under Obamacare may be structuring drug coverage in a way that dissuades people with HIV-AIDS from becoming their customers, according to a study published on Wednesday in the New England Journal of Medicine.
LONDON - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.
BANGKOK (Thomson Reuters Foundation) - The Asia-Pacific region will not meet the goal of ending the HIV epidemic in 15 years unless it changes laws and attitudes hostile to people living with HIV, the head of the United Nations agency on AIDS said on Wednesday.
NEW YORK - President Barack Obama's plan to put the United States at the forefront of individually tailored medical treatment should give a much-needed boost to research in the field but experts say it won't work without reforms to healthcare, including drug testing and insurance.
- UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.
(Reuters Health) – - Adding spice – in the form of curcumin supplements – to the daily diets of people with risk factors for heart disease may lower inflammation, a new study suggests.
(Reuters Health) – A large international analysis finds that statin drugs reduce heart risk factors like high cholesterol as effectively in women as they do in men.
- UK retailer Tesco Plc has recalled its No Added Sugar Double Concentrate Apple and Blackcurrant squash drink after getting complaints from customers regarding a foul smell coming from them.
NEW YORK - When patients with Parkinson's disease received an injection described as an effective drug costing $1,500 per dose, their motor function improved significantly more than when they got one supposedly costing $100, scientists reported on Wednesday.